About the Company
immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $IMVT News
Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
5 Oversold Healthcare Stocks To Buy Right Now
In this article, we will be taking a look at 5 oversold healthcare stocks to buy right now.
Immunovant, Inc. Is Worried About This – Should You Be Worried Too?
Immunovant, Inc. (IMVT) has disclosed a new risk, in the Share Price & Shareholder Rights category. Immunovant, Inc., upon exceeding the market value threshold with its common stock, will ...
Immunovant Awarded U.S. Patent for IMVT-1402
Patent also includes methods of use and methods of manufacturing claims NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to ...
Immunovant Inc CFO Eva Barnett Sells 2,930 Shares
On February 22, 2024, Eva Barnett, the Chief Financial Officer of Immunovant Inc (NASDAQ:IMVT), sold 2,930 shares of the company. The transaction was filed with the SEC and can be found in detail ...
Immunovant Stock (NASDAQ:IMVT), Quotes and News Summary
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following ...
Immunovant Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Immunovant Awarded U.S. Patent for IMVT-1402
Composition of matter patent issued with coverage until June 2043 Patent also includes methods of use and methods of manufacturing claims NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. ...
Immunovant Inc.: Immunovant Awarded U.S. Patent for IMVT-1402
Composition of matter patent issued with coverage until June 2043Patent also includes methods of use and methods of manufacturing claims NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc.
Loading the latest forecasts...